Hardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth

Dow Jones received a payment from EQS/DGAP to publish this press release.

Hardman & Co Research 
Hardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: 
solid growth 
 
27-Sep-2018 / 07:15 GMT/BST 
 
*Hardman & Co: 2018 full-year results: solid growth* 
 
AGY is a long-established specialist in the prevention, diagnosis and 
treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy 
immunotherapy (AIT), continues to gain market share despite being available in 
the EU only on a 'named-patient' basis. The Phase III trial, designed to 
obtain approval for PQ Birch as a biologic in Europe, is well advanced and 
will report data by the end of 2018. As discussed at the interim stage, 
underlying sales growth was affected by a low pollen season in central Europe. 
Full-year results suggest that this has remained a difficult market, but one 
in which AGY has continued to gain market share.Please click here for the full 
report: 
 
http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics- 
documents/27.09.18-2018-full-year-results-solid-growth.pdf [1] 
 
+------------------------+----------------+--------------------+ 
|*To contact us:*        |*Contacts:*     |                    | 
|                        |                |[e-mail] | 
|Hardman & Co            |Dr Martin Hall  |[e-mail]| 
|35 New Broad Street     |Dr Dorothea Hill|[e-mail] | 
|London                  |Dr Gregoire Pave|                    | 
|EC2M 1NH                |                |                    | 
|www.hardmanandco.com    |[phone]|                    | 
|*Follow us on Twitter*  |                |                    | 
|@HardmanandCo           |                |                    | 
+------------------------+----------------+--------------------+ 
 
*Hardman & Co Research can still be accessed for free after MiFID II. Please 
*click here [2] *to read the statement.* 
 
*About Hardman & Co:* For the past 21 years Hardman has been producing 
specialist research designed to improve investors' understanding of companies, 
sectors, industries and investment securities. Our analysts are highly 
experienced in their sectors, and have often been highly rated by professional 
investors for their knowledge. Our focus is to raise companies' profiles 
across the world with high-quality research, investor engagement programmes 
and advisory services. 
 
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative 
of Capital Markets Strategy Ltd and is authorised and regulated by the 
Financial Conduct Authority; our FCA registration number is 600843. Hardman 
Research Ltd is registered at Companies House with number 8256259. 
 
Our research is provided for the use of the professional investment community, 
market counterparties and sophisticated and high net worth investors as 
defined in the rules of the regulatory bodies. It is not intended to be made 
available to unsophisticated retail investors. Anyone who is unsure of their 
categorisation should consult their professional advisors. This research is 
neither an offer, nor a solicitation, to buy or sell any security. Please read 
the note for the full disclaimer. 
 
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
727781 27-Sep-2018 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ab27d344919fed4f4b1471a43f146f51&application_id=727781&site_id=vwd&application_name=news 
2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=5a632f52f80bd372265e4041a743aa1c&application_id=727781&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

September 27, 2018 02:15 ET (06:15 GMT)